Anthony Letai, MD, PhD, was sworn in as the 18th National Cancer Institute (NCI) Director Sept. 29. Dr. Letai brings a distinguished background in oncology and cancer research, having served as professor of medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute. His work has focused on cell death in cancer, the development of treatments and the identification of biomarkers. Letai will lead the largest funder of cancer research in the world, with a current budget of $7.2 billion.
As he begins his tenure, NCI has released its Fiscal Year (FY) 2027 Annual Plan and Professional Judgment Budget Proposal, requesting $11.5 billion for NCI in FY 2027. The proposal outlines the optimal level of investment needed to capitalize on emerging opportunities in cancer research. The FY 2027 request represents a $4.3 billion increase over NCI’s FY 2025 appropriation and approximately $7 billion more than the FY 2026 President’s budget request.
Key areas of proposed investment include:
ACR® has a longstanding relationship with NCI and remains committed to supporting ongoing and future advocacy efforts. For more information or if you have questions, contact Katie Grady, ACR Government Affairs Director.
2027 Medicare Advantage Final Rule, Rate Released
CMS finalized the 2027 Medicare Advantage and Part D rule, updating benefits, cost sharing, Star Ratings policies, and payment rates for plans.
Read morePhysician Groups Warn Visa Delays Could Impact Patient Care
More than 30 medical organizations, including the ACR®️, urged federal officials to address immigration barriers preventing international medical graduates (IMGs) from lawfully entering or remaining in the U.S.
Read moreACR Submits Testimony to Congress
ACR®️ submitted testimony to the U.S. House Committee on Appropriations Labor urging strong federal funding for medical research in federal fiscal year 2027.
Read more